Clinical Experience of Interferon Alfa-2a Treatment for XXXX in Beh  et's Disease.

@entity1 @entity32 @entity5863 @entity233 @entity1333 @entity9645 @entity1596 @entity228 @entity191 @entity205 @entity195 @entity1499 @entity4816 @entity479
@entity195 ( @entity195 ) involves multisystem @entity1333 of unknown origin. Ocular manifestations of @entity195 mostly include bilateral @entity5863 and @entity4816 , which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Beh  et @entity1596 , mainly in Germany and @entity233 . Nonetheless, there is so far no consensus about the ideal treatment regimen of IFN for Beh  et @entity1596 . We report our experience of IFN treatment in five Korean @entity195 @entity1 with refractory @entity1596 . All @entity1 @entity9645 ; one @entity1 had a positive pathergy test and 2 showed the presence of HLA-B51. Immunosuppressive agents used prior to IFN treatment included @entity205 and @entity1499 . The IFN treatment was commenced with a dose of 6-9 MIU/day for 7 days, adjusted according to individual ocular manifestations, tapered down to 3 MIU three times in a week, and then discontinued. All @entity1 showed positive response to IFN treatment; 50% of them showed complete response without additional major @entity32 during the follow-up period. @entity191 also improved after IFN treatment in most cases. After treatment, the relapse rate and the required dose of oral @entity228 were decreased in most cases, showing a significant @entity479 -sparing effect. However, the visual acuity was not improved in most cases due to irreversible macular sequelae. Despite the small sample size of this study, we suggest that, in Korean @entity1 , IFN is an effective treatment modality for @entity195 @entity1596 as was observed in German and Turkish @entity1 .
